As 2022 proves to be a year of missed predictions and uncertainty, we are using this year's BIO notebook to provide additional context by reviewing different industry metrics to provide more perspective to the comments coming from the meeting.
Biotechnology stock valuations are down 30%-50% over the past year, depending on which index you track, impacting the ability of private drug developers to go public and for public companies to raise cash in follow-on offerings, so companies are looking for alternative strategies for managing their operations and keeping R&D programs on
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?